StonvexLoading…
StonvexStonvexStonvexCore line items from ASTH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $3.18B | $2.03B | $1.39B | $1.14B |
Operating Income | $78.53M | $89.35M | $84.61M | $104.27M |
Net Income | $22.49M | $43.15M | $60.72M | $45.17M |
EPS (Diluted) | $0.46 | $0.90 | $1.29 | $0.99 |
Total Assets | $2.22B | $1.35B | $933.36M | $966.21M |
Total Liabilities | $1.66B | $840.73M | $522.59M | $407.67M |
Cash & Equivalents | $429.47M | $288.45M | $293.81M | $288.03M |
Free Cash Flow OCF − CapEx | $104.49M | $44.17M | $39.70M | $59.19M |
Shares Outstanding | 48.89M | 47.93M | 46.94M | 45.60M |